OBJECTIVES: The objective of this double-blind, randomized study was to determine the safety and efficacy of intracoronary radiation therapy (ICRT) with a dose of 17 Gray (Gy) compared to the currently recommended dose prescription of 14 Gy for the treatment of in-stent restenosis within bare metal stents. BACKGROUND: While gamma ICRT for in-stent restenosis has been proven efficacious, the optimal dose is unknown, and radiation failure due to recurrent neointimal hyperplasia remains a significant clinical problem for some patients. A higher radiation dose may improve outcomes, but may potentially increase adverse events. METHODS: Following coronary intervention, 336 patients with in-stent restenosis were randomly assigned to receive ICRT with either 14 Gy or 17 Gy at 2 mm from an 192-iridium source. RESULTS: At 8-month follow up, fewer patients in the 17 Gy group underwent target lesion revascularization (TLR ≤ 15.2% versus 27.2%; p ≤ 0.01), target vessel revascularization (21.3% versus 33.1%; p ≤ 0.02), or reached the composite endpoint of death, myocardial infarction, thrombosis, or TLR (17.1% versus 28.4%; p ≤ 0.02). There were no differences in late thrombosis or mortality between treatment groups. There was a strong trend toward reduced in-lesion late loss (0.36 ± 0.63 mm vs. 0.51 ± 0.64 mm; p ≤ 0.09) and a significantly lower rate of binary restenosis (23.9% versus 38.1%; p ≤ 0.031) in the high dose group. CONCLUSIONS: Gamma ICRT with 17 Gy is safe and, compared to 14 Gy, reduces recurrent stenosis and clinical events at 8-month follow up. An increase in the currently recommended gamma radiation dose prescription from 14 Gy to 17 Gy should be strongly considered.
|Number of pages||5|
|Journal||Journal of Invasive Cardiology|
|State||Published - Apr 2006|